Zenas BioPharma (ZBIO) Long-Term Deferred Tax (2023 - 2026)

Zenas BioPharma (ZBIO) posted quarterly Long-Term Deferred Tax of $439000.0 for Q1 2026, down 38.08% quarter-over-quarter from $709000.0 in Q4 2025.

Zenas BioPharma (ZBIO) Long-Term Deferred Tax (2023 - 2026) Analysis & Trends

Zenas BioPharma's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $439000.0 for Q1 2026.

In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $439000.0; the TTM figure through Mar 2026 stood at $439000.0 (changed N/A YoY), while the FY2025 annual figure was $709000.0, changed N/A from the prior year.
Long-Term Deferred Tax for Q1 2026 stood at $439000.0, down from $709000.0 in the prior quarter.
The five-year high for Long-Term Deferred Tax was $1.4 million in Q4 2023, with the low at $439000.0 in Q1 2026.
The 3-year median for Long-Term Deferred Tax is $773000.0 (2025), against an average of $846250.0.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-

Download Data